4-Azido-1-propan-2-ylpiperidine | 1175146-71-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Azido-1-propan-2-ylpiperidine
• CAS: 1175146-71-0
• 化学式: C₈H₁₆N₄
• 分子量: 168.242
• InChiKey: UXDHTMQYMQZSEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  17.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  丙醛二乙基乙缩醛 、 4-Azido-1-propan-2-ylpiperidine 在 sodium ascorbate 、 copper(II) sulfate 作用下， 生成
  参考文献：
  名称：

  Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-α production in human whole blood

  摘要：

  Tpl2 (cot/MAP3K8) is an upstream kinase of MEK in the ERK pathway. It plays an important role in Tumor Necrosis Factor-alpha (TNF-alpha) production and signaling. We have discovered that 8-halo-4-(3-chloro-4-fluorophenylamino)-6-[(1H-[ 1,2,3]triazol-4-ylmethyl)-amino]-quinoline-3-carbonitriles (4) are potent inhibitors of this enzyme. In order to improve the inhibition of TNF-alpha production in LPS-stimulated human blood, a series of analogs with a variety of substitutions around the triazole moiety were studied. We found that a cyclic amine group appended to the triazole ring could considerably enhance potency, aqueous solubility, and cell membrane permeability. Optimization of these cyclic amine groups led to the identification of 8-chloro-4-(3-chloro-4-fluorophenylamino)-6-((1-(1-ethylpiperidin-4-yl)-1H-1,2,3-triazol- 4-yl) methylamino)quinoline-3-carbonitrile (34). In a LPS-stimulated rat inflammation model, compound 34 showed good efficacy in inhibiting TNF-alpha production. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.05.009

文献信息

• Design, Synthesis and Pharmacokinetic Evaluation of a Novel Series of Triazole-Based Src Kinase Inhibitors with Anti-proliferative Activity
  作者：Shaojun Chen、Chuansheng Guo、Shiting Shi、Yanyan Shi、Du Fang、Houxing Fan

  DOI：10.2174/157018011793663930

  日期：2011.1.1

  Src has been recognized as an important therapeutic target for the treatment of cancer. A novel series of triazole- based Src inhibitors were synthesized and evaluated for their anti-proliferative activities in vitro against human lung cancer A549 cells with Bosutinib as reference compound, most of the compounds showed more potent activity than Bosutinib. Compounds 6 and 8 were further subjected to pharmacokinetic performance assessment, both the compounds displayed low plasma concentrations and short half-time.

  Src 已被公认为治疗癌症的重要靶点。研究人员合成了一系列新型三唑类 Src 抑制剂，并以博舒替尼为参比化合物，在体外评估了它们对人类肺癌 A549 细胞的抗增殖活性。化合物 6 和 8 还进行了药代动力学性能评估，结果表明这两种化合物的血浆浓度较低，半衰期较短。